

C-2024

# **Bleeding Disorder Therapy Order Form**

Patient Name:	DOB:	Phone:		
Address:	City:		State:	Zip:

#### 1. Please submit with form

- Copy of insurance card Patient demographics History & physical Recent clinic notes
- Labs pertaining to therapy (ex. factor levels, inhibitor testing, or other documentation supporting diagnosis)
- 2. Patient information: Male Female Height: in cm Weight: lbs kg NKDA Line type: PIV PICC Port No. of lumens Allergies: Is patient new to this therapy?  $\Box$ No  $\Box$ Yes History of inhibitor? No Yes: Is patient/caregiver independent with infusing factor? Yes No Nursing services needed? Yes No When is medication needed (upcoming procedure, active bleeding, etc.):

Factor X deficiency

### 3. Diagnosis and Clinical Information

### ICD-10 Code (required):

		racior A denciency
Hemophilia A (Factor VIII)	Mild Mod Severe	Factor XIII deficiency
Hemophilia B (Factor IX)	Mild Mod Severe	Glanzmann's Thrombasthenia
Von Willebrand, type 1	2 3 Subtype:	Wiskott-Aldrich Syndrome
Factor VII deficiency		Other:

## 4. Prescription Information

Factor Replacem	nt Therapy (Dose dispensed may be +/-10% unless otherwise specified)	
Prophylaxis	Product: Dose: units VWF:RCo Give IV once every days weel Dther:	k(s)
. ,	Dispense: 1 month supply / Refill x 6 months 1 year Other:	
<b>On-Demand</b> (PRN bleeding,	Product: Dose: units VWF:RCo Give IV once every hours days needed for bleed, procedure, or as directed. Other:	; as
procedure, or as directed)	Dispense: total doses (OR: minor doses, major doses) / Refill x Patient to keep doses in stock / Keep at least 3 day supply in home	
□ Other	Product: Dose: units VWF:RCo for IV administratio Frequency / directions:	n
	Dispense: doses / Refill x Other:	
Administration	⊠RN (or caregiver/patient if independent) to start peripheral IV or use existing CVC ⊠Flush IV catheter with NS & heparin, if indicated, per PromptCare policy and procedure Other:	

Hemlibra (Emicizum	nab) Therapy
Loading Doses	3 mg/kg once weekly for 4 weeksOther:Dosing weight:kgBegin maintenance doseweeks after final loading doseDispense:Quantity sufficient to complete loading dose regimen ORdoses/No refills
Maintenance Dose	1.5 mg/kg weekly3 mg/kg every 2 weeks6 mg/kg every 4 weeksOther:Dosing weight:kgDispense 1 month supply / Refill x

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of fallure to maintain is confidentially could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.

Oral Medications				
Medication	Aminocaproic acid 0.25 g/mL oral <b>solution</b> Aminocaproic acid <b>tablets</b> ( 500 mg or 1000 mg tablets) Tranexamic acid 650 mg tablets			
Directions	Give mg mg/kg mL by mouth every procedure, or as directed. Other:	hours as needed for bleeding,		
Quantity	Dispense: tablets OR mL OR:	/ Refill x		

Desmopressin (DDAVP)	
Subcutaneous injection (desmopressin 4 mcg/mL)	Give mcg mcg/kg mL subcutaneously, frequency: Give one dose 30 to 60 minutes prior to procedure Other: Dispense dose(s) / Refill x
Nasal spray (desmopressin 1.5 mg/mL)	<ul> <li>☑ Dose based on patient weight as follows:         <ul> <li>Weight &lt;50 kg: administer 150 mcg (1 spray) in a single nostril</li> <li>Weight ≥50 kg: administer 150 mcg (1 spray) in each nostril (total dose 300 mcg)</li> </ul> </li> <li>Directions:         <ul> <li>Give one dose as needed for bleeding, may repeat after 8-12 hours then daily up to a maximum of 3 days</li> <li>Give one dose 2 hours prior to procedure</li> <li>Other:</li> </ul> </li> </ul>

Dispense all medical supplies necessary for administration of prescribed medications

Provide skilled nursing to administer/teach preparation and infusion of prescribed medications Other:

#### 5. Adverse Reaction Orders (if applicable):

6. Prescriber Information				
Prescriber Name:		Office Contact:		
Address:		City:	State:	Zip:
Phone:		Fax:		
License #:	DEA #:	NPI:		
Physician Signature (Substitution Permitted)	Date	Physician Signature (Disp	ense as Written)	Date

By signing I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment. PromptCare has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.